Navigation Links
Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line
Date:5/3/2010

ondition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development, to expand manufacturing and commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 ... US demand for specialty biocides is forecast to ... 2018. In volume terms, demand is projected to increase ... the same period. A strong rebound in construction expenditures ... and paint and coatings markets, while growth in consumer ...
(Date:9/22/2014)... DUBLIN , Sept. 22, 2014 ... the "Global and Chinese Microcrystalline Cellulose Industry Report ... The Global and Chinese Microcrystalline Cellulose Industry Report 2014 ... state of the global microcrystalline cellulose industry with a ... provides a basic overview of the industry including definitions, ...
(Date:9/22/2014)... FierceBiotech today announced its annual “Fierce ... of 2014. FierceBiotech editors John Carroll and Damian ... winners. Those selected are identified as some of ... , "It's always a lot of fun ... companies," said Carroll. "This year in particular you'll find ...
(Date:9/22/2014)... , Sept. 22, 2014 Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Robert Bazemore as Chief Operating Officer.  Reporting ... and Chief Executive Officer, Robert will oversee the ... program, sebelipase alfa for LAL Deficiency, and will ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Global and Chinese Microcrystalline Cellulose Industry Report 2014 2FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4
... Last night, as I watched my brothers set off marginally ... checked e-mail since Sunday morning, and my mobile phone was ... of July weekend, the mid-summer respite, and I felt anything ... hours even over a holiday weekend comes with ...
... as businesses seek to protect and enhance the value ... result of the business' products and services. Each year, ... many of them for federal trademark registration. Indeed, applications ... good leading indicator of economic conditions (a steep drop ...
... Madison, Wis. The National Institutes of ... a $4 million Fast-Track SBIR grant from the ... Diseases. , ,Under this grant, Stratatech will work ... substitute with enhanced antimicrobial and angiogenetic properties for ...
Cached Biology Technology:Declaring independence from technology (sort of) 2Declaring independence from technology (sort of) 3Why file for trademark protection? 2Why file for trademark protection? 3Why file for trademark protection? 4
(Date:9/22/2014)... in recent years has been identified as the plant,s ... aroma also summons beneficial insects to the rescue. , ... the environment via the emission of volatile organic compounds, ... wasps to come to the plant that is being ... Dr. Michael Kolomiets, Texas A&M AgriLife Research plant pathologist ...
(Date:9/22/2014)... in a plant,s biological clock one that modulates ... , Transcription factors, or genetic switches, drive gene expression ... light, rain, soil quality, or even animals grazing on ... one, called FBH1, that reacts to temperature tweaking ... keeping it on a consistent track. , "Temperature helps ...
(Date:9/22/2014)... CITY (September 22, 2014)The Brain & Behavior ... award of NARSAD Young Investigator Grants valued ... of the world,s most promising young scientists. ... groundbreaking neurobiological research will seek to identify ... for psychiatric disorders that affect one in ...
Breaking Biology News(10 mins):Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3Genetic switch regulates a plant's internal clock based on temperature 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2
... for cystic fibrosis, HIV-fighting ,Trojan horses, new pharmaceuticals from ... to discover medications of the future. ,On 24 August, ... an international conference in Gothenburg, Sweden. In ... to investigate, and eventually control, the behavior of cells. ...
... researcher is challenging health standards that consider nitrates and ... research suggests that although there are negative health effects ... nitrates in groundwater, nitrates and nitrites -- as they ... Nitrate and nitrite are naturally occurring ions associated ...
... visceral fat, more commonly called belly fat, is known to ... causes visceral fat to accumulate? The culprit is likely ... hormone balance that occurs during the menopause transition, according to ... factors we analyzed that could possibly account for the increase ...
Cached Biology News:10th Functional Genomics: Chemical Biology 2009 2Research supports calls to study health benefits of nitrate, nitrite 2Increase in visceral fat during menopause linked with testosterone 2
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... has improved stability and convenience from the former ... has overcome this problem but also produced some ... the formulation of HRP conjugated antibody from lyophilized ... change, the stability of the conjugate has improved ...
... suitable for a wide range of molecular ... Pulsed Field Gel Electrophoresis (PFGE). Due to ... Multi ABgarose can effectively separate large DNA ... turn means reduced band diffusion, a problem ...
Biology Products: